{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T22:33:59Z","timestamp":1694730839231},"reference-count":30,"publisher":"Consilium Medicum","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ter. arkh."],"published-print":{"date-parts":[[2014]]},"DOI":"10.17116\/terarkh2014861242-47","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T17:07:12Z","timestamp":1460653632000},"page":"42","source":"Crossref","is-referenced-by-count":5,"title":["Etoricoxib in the treatment of active sacroiliitis in patients with axial spondyloarthritis, including ankylosing spondylitis"],"prefix":"10.26442","volume":"86","author":[{"given":"I. Z.","family":"Ga\u012ddukova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. P.","family":"Rebrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. F.","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. V.","family":"Kirsanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","reference":[{"key":"key-10.17116\/terarkh2014861242-47-1","unstructured":"\u041a\u0430\u0440\u0430\u0442\u0435\u0435\u0432 \u0410.\u0415. Nesteroidnye protivovospalitel'nye preparaty v sovremennoi klinicheskoi praktike: \"za\" bol'she, chem \"protiv\". Sovr revmatol 2008; 1: 70-77."},{"key":"key-10.17116\/terarkh2014861242-47-2","doi-asserted-by":"crossref","unstructured":"Poddubnyy D., van der Heijde D. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Rheum Dis Clin North Am 2012; 38 (3): 601-611.","DOI":"10.1016\/j.rdc.2012.08.005"},{"key":"key-10.17116\/terarkh2014861242-47-3","doi-asserted-by":"crossref","unstructured":"Braun J., van den Berg R., Baraliakos X. et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70 (6): 896-904.","DOI":"10.1136\/ard.2011.151027"},{"key":"key-10.17116\/terarkh2014861242-47-4","doi-asserted-by":"crossref","unstructured":"Wanders A., van der Heijde D., Landewe R. et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52: 1756-1765.","DOI":"10.1002\/art.21054"},{"key":"key-10.17116\/terarkh2014861242-47-5","doi-asserted-by":"crossref","unstructured":"Poddubnyy D., Rudwaleit M., Haibel H. et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012; 71 (10): 1616-1622.","DOI":"10.1136\/annrheumdis-2011-201252"},{"key":"key-10.17116\/terarkh2014861242-47-6","doi-asserted-by":"crossref","unstructured":"Poddubnyy D., Haibel H., Listing J. et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012; 64 (5): 1388-1398.","DOI":"10.1002\/art.33465"},{"key":"key-10.17116\/terarkh2014861242-47-7","doi-asserted-by":"crossref","unstructured":"Patrignani P., Capone M.L., Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin Pharmacother 2003; 4 (2): 265-284.","DOI":"10.1517\/eoph.4.2.265.21085"},{"key":"key-10.17116\/terarkh2014861242-47-8","doi-asserted-by":"crossref","unstructured":"Machado P., Landew\u00e9 R.B., Braun J. et al. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann Rheum Dis 2012; 71 (12): 2002-2005.","DOI":"10.1136\/annrheumdis-2012-201999"},{"key":"key-10.17116\/terarkh2014861242-47-9","doi-asserted-by":"crossref","unstructured":"Dougados M., van der Heijde D., Sieper J. et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2014; 66 (8): 2091-2102.","DOI":"10.1002\/art.38721"},{"key":"key-10.17116\/terarkh2014861242-47-10","doi-asserted-by":"crossref","unstructured":"Goh L., Suresh P., Gafoor A. et al. Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings. Clin Rheumatol 2008; 27 (4): 449-455.","DOI":"10.1007\/s10067-007-0726-7"},{"key":"key-10.17116\/terarkh2014861242-47-11","doi-asserted-by":"crossref","unstructured":"Rudwaleit M., Schwarzlose S., Hilgert E.S. et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008; 67 (9): 1276-1281.","DOI":"10.1136\/ard.2007.073098"},{"key":"key-10.17116\/terarkh2014861242-47-12","doi-asserted-by":"crossref","unstructured":"atients with ankylosing spondylitis eligible for anti-tumour Lories R.J. Etoricoxib and the treatment of ankylosing spondylitis. Expert Opin Drug Metab Toxicol 2012; 8 (12): 1599-1608.","DOI":"10.1517\/17425255.2012.741120"},{"key":"key-10.17116\/terarkh2014861242-47-13","doi-asserted-by":"crossref","unstructured":"Jarrett S.J., Sivera F., Cawkwell L.S. et al. MRI and clinical findings in p necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 2009; 68 (9): 1466-1469.","DOI":"10.1136\/ard.2008.092213"},{"key":"key-10.17116\/terarkh2014861242-47-14","doi-asserted-by":"crossref","unstructured":"Rudwaleit M., Landewe R., van der Heijde D. et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68 (6): 770-776.","DOI":"10.1136\/ard.2009.108217"},{"key":"key-10.17116\/terarkh2014861242-47-15","unstructured":"Bennett P.H., Burch T.A. Population studies of the rheumatic diseases. Amsterdam: Excerpta Medica Foundation International Congress Series 148. 1966: 456-457."},{"key":"key-10.17116\/terarkh2014861242-47-16","doi-asserted-by":"crossref","unstructured":"van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27 (4): 361-368.","DOI":"10.1002\/art.1780270401"},{"key":"key-10.17116\/terarkh2014861242-47-17","doi-asserted-by":"crossref","unstructured":"Rudwaleit M., Jurik A.G., Hermann K.G. et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group. Ann Rheum Dis 2009; 68 (10): 1520-1527.","DOI":"10.1136\/ard.2009.110767"},{"key":"key-10.17116\/terarkh2014861242-47-18","unstructured":"Garrett S., Jenkinson T., Kennedy L. et al. New approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-2222."},{"key":"key-10.17116\/terarkh2014861242-47-19","doi-asserted-by":"crossref","unstructured":"Lukas C., Landewe R., Sieper J. et al; Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68 (1): 18-24.","DOI":"10.1136\/ard.2008.094870"},{"key":"key-10.17116\/terarkh2014861242-47-20","doi-asserted-by":"crossref","unstructured":"Laine L., Curtis S.P., Cryer B. et al.; MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac. Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet 2007; 369: 465-473.","DOI":"10.1016\/S0140-6736(07)60234-7"},{"key":"key-10.17116\/terarkh2014861242-47-21","doi-asserted-by":"crossref","unstructured":"Hunt R.H., Harper S., Watson D.J. et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98 (8): 1725-1733.","DOI":"10.1111\/j.1572-0241.2003.07598.x"},{"key":"key-10.17116\/terarkh2014861242-47-22","doi-asserted-by":"crossref","unstructured":"Martina S.D., Vesta K.S., Ripley T.L. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005; 39 (5): 854-862.","DOI":"10.1345\/aph.1E543"},{"key":"key-10.17116\/terarkh2014861242-47-23","doi-asserted-by":"crossref","unstructured":"Van der Heijde D., Baraf H.S., Ramos-Remus C. et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52: 1205-1215.","DOI":"10.1002\/art.20985"},{"key":"key-10.17116\/terarkh2014861242-47-24","doi-asserted-by":"crossref","unstructured":"Poddubnyy D., Gaydukova I., Hermann K.G. et al. Performance of magnetic resonance imaging for the detection of chronic structural changes in the sacroiliac joints as compared to conventional x-rays in axial spondyloarthritis. J Rheumatol 2013; 40 (9): 1557-1565.","DOI":"10.3899\/jrheum.130141"},{"key":"key-10.17116\/terarkh2014861242-47-25","unstructured":"\u0420\u0435\u0431\u0440\u043e\u0432\u0430 \u041e.\u042e. Statisticheskii analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA. M: Media-Sfera 2002."},{"key":"key-10.17116\/terarkh2014861242-47-26","doi-asserted-by":"crossref","unstructured":"Amor B., Dougados M., Khan M.A. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995; 21 (1): 117-128.","DOI":"10.1016\/S0889-857X(21)00374-4"},{"key":"key-10.17116\/terarkh2014861242-47-27","unstructured":"Maquirriain J., Kokalj A. Management of acute Achilles tendinopathy: effect of etoricoxib on pain control and leg stiffness. Georgian Med News 2013; 222: 36-43."},{"key":"key-10.17116\/terarkh2014861242-47-28","doi-asserted-by":"crossref","unstructured":"Poddubnyy D., Rudwaleit M., Haibel H. et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70 (8): 1369-1374.","DOI":"10.1136\/ard.2010.145995"},{"key":"key-10.17116\/terarkh2014861242-47-29","doi-asserted-by":"publisher","DOI":"10.1002\/art.38792. [Epub ahead of print]"},{"key":"key-10.17116\/terarkh2014861242-47-30","doi-asserted-by":"crossref","unstructured":"Baraliakos X., Haibel H., Listing J. et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014; 73(4): 710-715.","DOI":"10.1136\/annrheumdis-2012-202698"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T21:27:52Z","timestamp":1655501272000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/terapevticheskij-arkhiv\/2014\/12\/downloads\/ru\/030040-36602014128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014]]}},"alternative-id":["terarkh2014861242-47"],"URL":"https:\/\/doi.org\/10.17116\/terarkh2014861242-47","relation":{},"ISSN":["0040-3660"],"issn-type":[{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}